N/A
N=44
Clinical Evaluation of the Picosure Laser for the Treatment of Unwanted Tattoos
Unwanted Tattoos
Bottom Line
View on ClinicalTrials.gov: NCT02103153 ↗Enrolled (actual)
44
Serious AEs
0.0%
Results posted
Feb 2021
Primary outcome: Primary: Tattoo Clearance Percentage Using a Photographic Scale — 84.7 percentage of clearance
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Picosure Laser System (Device)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Cynosure, Inc.
- Primary completion
- Jan 2017
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Tattoo Clearance Percentage Using a Photographic Scale |
84.7 | — |
| SECONDARY Investigator Satisfaction |
0; 1; 19; 14 | — |
| SECONDARY Subject Satisfaction |
1; 5; 17; 11 | — |
Summary
The purpose of this study is to evaluate the PICOSURE Laser System for the treatment of unwanted tattoos
Eligibility Criteria
Inclusion Criteria
- Is a healthy non-smoking (must have quit 6 months prior) male or female between 18 and 65 years old.
- Is willing to consent to participate in the study.
- Is willing to comply with all requirements of the study including being photographed, following post treatment care and attending all treatment and follow up visits
- Has unwanted non-cosmetic tattoo containing red ink, that has not previously been treated, and wishes to undergo laser treatment
Exclusion Criteria
- The subject is female and pregnant, has been pregnant within the last 3 months, is currently breast feeding or planning a pregnancy during the study period.
- The subject is hypersensitive to light exposure OR takes photo sensitized medication.
- The subject has active or localized systemic infections.
- The subject has a coagulation disorder or is currently using anti-coagulation medication (including but not limited to heavy aspirin therapy {greater than 81 mg per day}).
- The subject has any condition which, in the investigator's opinion, would make it unsafe for the subject to participate in this research study.
- The subject is currently enrolled in an investigational drug or device trial, or has received an investigational drug or been treated with an investigational device within 3 months prior to entering this study.
- The subject has used Accutane within 6 months prior to enrollment.
- The subject has the need to be exposed to artificial tanning devices or excessive sunlight during the trial.
- The subject has had prior treatment with parenteral gold therapy (gold sodium thiomalate).
- The subject has a history of keloids.
- The subject has evidence of compromised wound healing.
- The subject has a history of basal cell carcinoma, squamous cell carcinoma or melanoma.
- The subject has a history of immunosuppression/immune deficiency disorders (including HIV infection or AIDS) or use of immunosuppressive medications or has an autoimmune disorder.
Data sourced from ClinicalTrials.gov (NCT02103153). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.